Aktiekursudvikling

WntResearch: Closer Than Ever

Case: WntResearch Closer than ever WntResearch has applied for their phase II trials regarding proof-of-concept for the FOXT-5 compound. Hence, WntResearch is closer than ever

Læs mere »
12. september 2018

Kapital Partner A/S

Jernbanegade 4, 3. th
1608 København V

CVR: 37364843

Privatlivspolitik  –  Cookies

Kontakt

Telefon: +45 8988 7846
E-mail: info@kapitalpartner.dk

Social media

Andre sites

Disclaimer

Kapital Partner udfører eller har inden for de seneste 12 måneder udført corporate finance, market relations, investor relations, Certified Adviser eller andre rådgivningsaktiviteter for følgende børsnoterede selskaber: Biosergen, InterMail, Pila Pharma, Hypefactors, Curasight, Evaxion, Re-Match, Audientes, Mdundo.com, Nexcom.